• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Century Therapeutics to Participate in Upcoming Investor Conferences in March

    2/25/26 8:00:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IPSC alert in real time by email

    PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced that the company will participate in the following upcoming investor conferences in March:

    • TD Cowen 46th Annual Health Care Conference: Fireside chat at 9:50 a.m. ET on Wednesday, March 4, 2026, in Boston, MA.



    • Leerink Partners Global Healthcare Conference: Fireside chat at 4:20 p.m. ET on Tuesday, March 10, 2026, in Miami, FL.



    A live webcast of the presentations will be available on the Investors page of Century's website at www.centurytx.com. Archived replays will be available for at least 30 days.

    About Century Therapeutics

    Century Therapeutics (NASDAQ:IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases, including type 1 diabetes, and cancer. The company's therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

    For More Information:

    Century Therapeutics

    Douglas Carr

    Senior Vice President, Finance

    investor.relations@centurytx.com

    JPA Health

    Sarah McCabe

    smccabe@jpa.com



    Primary Logo

    Get the next $IPSC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IPSC

    DatePrice TargetRatingAnalyst
    5/27/2026$8.00Outperform
    Mizuho
    2/25/2026Buy
    TD Cowen
    8/8/2024$6.00Buy
    Rodman & Renshaw
    8/28/2023$28.00 → $5.00Overweight → Neutral
    JP Morgan
    12/27/2022$19.00Buy
    Chardan Capital Markets
    10/31/2022$15.00Buy
    Guggenheim
    10/10/2022$28.00Buy
    Canaccord Genuity
    5/23/2022$27.00Buy
    H.C. Wainwright
    More analyst ratings

    $IPSC
    Leadership Updates

    Live Leadership Updates

    View All

    Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

    NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company's Board of Directors. "Brent is an accomplished pharma industry leader with deep expertise across research, development, and commercialization of life-saving drugs," said Rachelle Jacques, Chair of the Corbus Board of Directors. "His proven record of delivering value-generating commercial successes and steering notable corporate evolutions adds distinctive perspective to the Corbus Board. We look forward to Bre

    5/14/26 8:00:00 AM ET
    $CRBP
    $IPSC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors

    PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As part of their appointments, Dr. Lee will serve as a member of the Audit and the Compensation Committees and Dr. Murphy will serve as a member of the Compensation and the Nominating and Corporate Governance Committees. "We are pleased to welcome Dr. Lee and Dr. Murphy to our Board at an important time for Century as we execute with discipline and

    12/9/25 8:00:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

    SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

    3/25/24 7:00:00 AM ET
    $IPSC
    $MIRM
    $RPHM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $IPSC
    Financials

    Live finance-specific insights

    View All

    Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

    - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 trial in relapsed/refractory (R/R) B-cell lymphoma to be presented at American Society for Clinical Oncology (ASCO) Annual Meeting - Ended 1Q24 with cash, cash equivalents, and invest

    5/9/24 7:30:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

    – Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data demonstrate six-month durable complete response in Dose Level 1 in a single patient following multiple cycles of CNTY-101 without lymphodepletion – – Pharmacokinetic data suggests CNTY-101 exposure may be maintained upon administration of additional cycles without lymphodepletion due to lack of observed allo-rejection – –   Company to host conference call on Monday, December 11 at 7:30 AM PT/10:30 AM ET to review ASH data including additional clinical results from Dose Level 1

    12/9/23 12:00:00 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

    PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas. In addition to updated preliminary clinical data as of a more re

    12/6/23 7:30:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Pfeiffenberger Brent covered exercise/tax liability with 31,172 shares, decreasing direct ownership by 0.84% to 3,679,786 units (SEC Form 4) to satisfy withholding tax

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    5/19/26 4:10:05 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP Finance & Operations Carr Douglas sold $618 worth of shares (264 units at $2.34), decreasing direct ownership by 0.05% to 506,997 units (SEC Form 4) (for withholding tax)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    5/6/26 5:27:26 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Murphy Martin Patrick

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    4/10/26 5:07:53 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Century Therapeutics with a new price target

    Mizuho initiated coverage of Century Therapeutics with a rating of Outperform and set a new price target of $8.00

    5/27/26 9:01:30 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on Century Therapeutics

    TD Cowen initiated coverage of Century Therapeutics with a rating of Buy

    2/25/26 7:49:49 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on Century Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $6.00

    8/8/24 10:22:51 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Century Therapeutics Inc.

    SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

    11/27/24 6:51:58 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

    SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

    11/14/24 5:46:35 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

    SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

    11/14/24 4:08:17 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

    Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)SAN FRANCISCO, June 2, 2026 /CNW/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT Biopharma, Inc. (NASDAQ:GTBP) recently put its third drug into the clinic — and the entire company has at times been valued at a small fraction of that. The gap between what the company is doing in the lab and what the market is paying for it is the whole story here, and a milestone reached in mid-May has brought it into sharp focus.

    6/2/26 9:02:00 AM ET
    $GTBP
    $INKT
    $IPHA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

    NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company's Board of Directors. "Brent is an accomplished pharma industry leader with deep expertise across research, development, and commercialization of life-saving drugs," said Rachelle Jacques, Chair of the Corbus Board of Directors. "His proven record of delivering value-generating commercial successes and steering notable corporate evolutions adds distinctive perspective to the Corbus Board. We look forward to Bre

    5/14/26 8:00:00 AM ET
    $CRBP
    $IPSC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Century Therapeutics Reports First Quarter Financial Results and Business Updates

    CNTY-813, Century's type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY‑813 preclinical data on June 8, 2026On track to advance CNTY‑308, Century's CD19‑targeted CAR‑iT cell therapy, into the clinic this yearCash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026 PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripoten

    5/13/26 8:00:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Cowan Chad bought $49,252 worth of shares (58,060 units at $0.85), increasing direct ownership by 6% to 1,045,087 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    12/29/25 4:52:27 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Pfeiffenberger Brent bought $30,352 worth of shares (52,000 units at $0.58), increasing direct ownership by 2% to 3,322,990 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    12/16/25 6:38:17 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Pfeiffenberger Brent bought $17,328 worth of shares (35,000 units at $0.50), increasing direct ownership by 1% to 3,271,453 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    11/20/25 6:02:42 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    SEC Filings

    View All

    SEC Form 424B7 filed by Century Therapeutics Inc.

    424B7 - Century Therapeutics, Inc. (0001850119) (Filer)

    5/21/26 5:01:29 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Century Therapeutics Inc.

    SCHEDULE 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

    5/15/26 4:19:04 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Century Therapeutics Inc.

    SCHEDULE 13G - Century Therapeutics, Inc. (0001850119) (Subject)

    5/15/26 8:14:32 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care